<DOC>
	<DOCNO>NCT02345044</DOCNO>
	<brief_summary>This study randomize , placebo-controlled , double-blind , multi-center study evaluate efficacy safety different dose CS-3150 compare placebo Japanese hypertensive subject . Primary endpoint change baseline sit systolic diastolic blood pressure .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety CS-3150 Japanese Hypertensive Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Male female subject age 20 year old informed consent Subjects essential hypertension ( Sitting SBP ≥ 140 mmHg &lt; 180 mmHg , Sitting DBP ≥ 90 mmHg &lt; 110 mmHg , 24hhr blood pressure 130 mmHg SBP 80 mmHg DBP ) Secondary hypertension malignant hypertension Diabetes mellitus albuminuria Serum potassium level &lt; 3.5 ≥ 5.1 mEq/L Reversed daynight life cycle include overnight worker eGFR &lt; 60 mL/min/1.73 m^2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
	<keyword>CS-3150</keyword>
	<keyword>Japanese</keyword>
</DOC>